Clinical Trial: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06823960) titled 'Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)' on Feb. 03.

Brief Summary: Observational, non-interventional, retrospective, multicentre study focusing on efficacy and safety of zanubrutinib in daily clinical practice in patients with relapsed/refractory (R/R) marginal zone lymphoma.

Study Start Date: Dec. 09, 2024

Study Type: OBSERVATIONAL

Condition: Marginal Zone Lymphoma(MZL)

Recruitment Status: RECRUITING

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Published by HT Digital Content Services with permissi...